Skip to content
Head to head

Xeris Pharmaceuticals vs Takeda Pharmaceutical

Side-by-side on the measures that matter, with a plain-English read. Full detail: XERS · TAK

Updated 3 minutes ago

1-year performance, rebased to 100

XERS +133.7%TAK +56.6%
It’s close.
XERSTAK
Snapshot
SectorDrug Manufacturers - Specialty & Generic--
Last price16.9721.77
Change today+2.11%+1.68%
1-year return+148.1%+57.5%
Market cap$3.10B$69.76B
52-week range5.25 – 17.2813.92 – 22.07
Valuation
P/E (TTM)-628.52311.00
P/E percentile, own 5-yr range0th100th
P/B63.561.50
Dividend yield0.00%1.44%
Profitability & growth
EPS (TTM)0.00-0.30
Net profit (TTM)$548.10K$-970.94M
Revenue (TTM)$368.26M$4.69T
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+44.2%+6.7%
Gross margin87.4%65.8%
Operating margin12.7%14.3%
Net margin-1.8%0.9%
Free cash flow (TTM)$72.62M$433.95B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership64.2%51.3%
Insider activity (12mo)17 buy / 33 sell19 buy / 31 sell
Short interest (% of float)4.9%0.1%
Analyst consensus83% buy / 17% hold (6)100% buy (1)
Analyst price target$17 (-3%)$50 (+132%)
StockVane view
StockVane Quant RatingC (98)C (90)
Company
Employees43547,029
Founded20051781

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.